2 transcripts
XFOR
Earnings call transcript
NASDAQ
2024 Q2
8 Aug 24
not carry short or long-term dose-related toxicities described with G-CSF use, and for an oral treatment that also increases ANC levels and lessens the risk
XFOR
Earnings call transcript
NASDAQ
2024 Q1
7 May 24
, the CIS poster revealed that long-term treatment with XOLREMDI was associated with durable improvements in neutrophil and lymphocyte counts as well
- Prev
- 1
- Next